OncoMatch/Clinical Trials/NCT06603870

Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis

Is NCT06603870 recruiting? Yes, currently enrolling (Sep 2026). This Phase 4 trial studies Apixaban for venous thromboembolism.

Phase 4RecruitingOttawa Hospital Research InstituteNCT06603870Data as of Sep 2026Location: Canada

Treatment: Apixaban — This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Apixaban

Cancer type

Tumor Agnostic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06603870 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify